Rationally-designed, D-conformation Antimicrobial Peptides as Novel Antibacterial Drug Candidates for the Treatment of Multi-drug-resistant Bacterial

Award Information
Agency:
Department of Defense
Branch
Navy
Amount:
$69,960.00
Award Year:
2009
Program:
STTR
Phase:
Phase I
Contract:
N00014-09-M-0358
Award Id:
90351
Agency Tracking Number:
N09A-033-0173
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
2256 Ash Street, Denver, CO, 80207
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
018876967
Principal Investigator:
Robert Hodges
Principal Investigator
(720) 339-1908
Robert.Hodges@UCHSC.edu
Business Contact:
David DeLong
Managing Member
(303) 921-5789
dd.bio.336@comcast.net
Research Institution:
University of Colorado Denver
Lora Milhelic
MS F428, Anschutz Medical
13001 E. 17th Place, Room W112
Aurora, CO, 80045
(303) 727-0090
Nonprofit college or university
Abstract
Antimicrobial resistance is among the most challenging problems in microbiology and clinical medicine, and the DOD has seen a dramatic increase of resistant strains of MRSA and multi-drug-resistant Acinetobacter baumanii (MDR-AB) emerging in combat- and non-combat-related healthcare settings. Virulent/MDR infections are developing single/ multiple routes of resistance to the thirteen classes of currently available antiobiotics. New drugs now in trials hold little promise for major advances. Our BioAMPS/U. of Colorado STTR team proposes to pursue the much needed next-generation solution. We have developed a portfolio of alpha-helical antimicrobial peptides that exhibit broad-spectrum in vitro activity, and in Phase I we intend to prove the feasibility of identifying one or more lead peptide compounds that will function as effective antibacterials against MDR infections. Our novel, proprietary peptides target only the cytoplasmic membrane and do not require an interaction with a stereoselective receptor or pathway-an advantage that holds great potential for eliminating development of resistance. In Phase I we will screen three structurally unique series (13 analogs) of our peptides against 15 strains/isolates of MRSA and MDR-AB obtained from throughout the world to identify one or more novel antibacterial drug candidates for follow-on development in a larger Phase II STTR project.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government